Last updated: October 18, 2026
Clocortolone pivalate is an established, prescription topical corticosteroid marketed primarily as a 0.1% cream. Its commercial opportunity is no longer based on exclusivity for the active ingredient. Value is concentrated in vehicle design, tolerability, dispensing systems, manufacturing efficiency, dermatology positioning, and differentiated topical dosage forms.
The strongest development strategies are low-irritancy cream reformulation, preservative reduction or elimination, improved cosmetic acceptability, metered dispensing, pediatric usability, and alternative vehicles such as lotion, ointment, gel, foam, or spray. Any product using a materially different vehicle or dosage form would require a regulatory pathway beyond a conventional abbreviated new drug application unless equivalence requirements are met.
What is clocortolone pivalate and how is it marketed?
Clocortolone pivalate is a synthetic topical corticosteroid used for inflammatory and pruritic corticosteroid-responsive dermatoses. The principal U.S. dosage form is clocortolone pivalate cream, USP 0.1%, historically marketed under the Cloderm brand and later supplied through generic products.
The product is generally considered a medium-potency topical corticosteroid. FDA labeling directs application as a thin film to affected areas, typically two or three times daily depending on the product label and clinical judgment. As with other topical corticosteroids, use is limited by potential local adverse effects, including skin atrophy, striae, telangiectasia, irritation, and secondary infection risk. Systemic absorption is more likely with large treatment areas, occlusion, damaged skin, prolonged use, or pediatric administration.[1]
Clocortolone pivalate is not an over-the-counter monograph corticosteroid. A commercial product remains prescription regulated in the United States.
What excipients are used in clocortolone pivalate cream?
The reference cream uses a conventional oil-in-water topical emulsion. Public labeling identifies excipients including fatty alcohols, glyceryl stearate, isopropyl myristate, mineral oil, polysorbate 60, propylene glycol, purified water, sorbitol solution, stearyl alcohol, and white petrolatum.[1]
| Excipient function |
Representative materials in labeled cream |
Commercial purpose |
| Emollient and occlusive phase |
Mineral oil, white petrolatum |
Reduces transepidermal water loss and improves moisturization |
| Emulsion structure |
Glyceryl stearate, cetyl alcohol, stearyl alcohol |
Provides viscosity, body, and phase stability |
| Emulsifier |
Polysorbate 60 |
Stabilizes the oil-in-water system |
| Solvent or humectant |
Propylene glycol, sorbitol solution |
Supports drug distribution and skin hydration |
| Lipophilic solvent |
Isopropyl myristate |
Improves spreadability and skin feel |
| Aqueous phase |
Purified water |
Provides the continuous phase |
The formulation is commercially serviceable but leaves room for development. The main constraints are steroid uniformity, physical stability, preservative control, skin tolerability, microbial protection, and maintenance of comparable drug release and delivery.
How can excipient selection differentiate clocortolone pivalate products?
Excipient differentiation should target measurable product attributes rather than ingredient novelty alone. The highest-value attributes are spreadability, residue, absorption profile, irritation potential, washability, storage stability, and patient adherence.
Low-irritancy strategy
Propylene glycol is widely used in topical products as a solvent and humectant, but it can cause irritation or allergic contact dermatitis in some patients. A reformulation could reduce propylene glycol concentration or replace part of its function with glycerol, pentylene glycol, butylene glycol, or another compatible humectant.
The tradeoff is that changing the solvent system can alter clocortolone pivalate solubility, particle state, release rate, and skin penetration. A lower-irritancy claim would require comparative clinical or dermatological evidence. The product cannot assume that removing a known irritant automatically creates a clinically superior formulation.
Preservative-reduction strategy
An emulsion containing water requires microbial control unless the packaging and manufacturing process support a validated alternative. Commercial options include:
- A conventional preservative system at the lowest effective concentration.
- A preservative-free product in a unit-dose or airless package.
- A low-water or anhydrous ointment.
- A self-preserving formulation with validated water activity and antimicrobial performance.
- A package that reduces repeated environmental contamination.
A preservative-free cream could command a premium in patients with sensitive skin, chronic dermatitis, or known preservative allergy. The cost burden would shift to packaging, manufacturing controls, microbial testing, and potentially shorter in-use periods.
Improved cosmetic profile
Mineral oil and petrolatum provide useful occlusion but can create a greasy residue. A more cosmetically elegant product could use lighter emollients, esters, silicones, or structured lipid systems. Candidate changes include substitution or reduction of mineral oil, lower petrolatum loading, and use of volatile or nonvolatile silicones.
The commercial objective is a cream that spreads rapidly, leaves less residue, and is acceptable for visible areas such as the face, hands, and neck. The formulation must still maintain the intended medium-potency corticosteroid delivery profile. Cosmetic improvement without adequate drug release would not create a viable product.
Barrier-repair positioning
Clocortolone pivalate can be paired with excipients associated with barrier support, such as ceramides, fatty acids, cholesterol, glycerol, or colloidal oatmeal. These ingredients may support a differentiated product for eczema-prone or xerotic skin.
The regulatory and marketing risk is claim expansion. A product may be positioned as a corticosteroid with moisturizing or barrier-support properties, but claims to treat atopic dermatitis, restore the skin barrier, or reduce relapse may require clinical evidence beyond the original clocortolone pivalate indication.
What formulations are protected or commercially available for clocortolone pivalate?
The established commercial form is the 0.1% cream. Potential differentiated dosage forms include:
| Dosage form |
Patient benefit |
Development complexity |
Commercial opportunity |
| Cream |
Familiar, broad use, moderate occlusion |
Low to moderate |
Generic substitution and branded reformulation |
| Ointment |
High occlusion, useful for thick or dry lesions |
Low |
Niche dermatology and severe xerosis |
| Lotion |
Better for large or hair-bearing areas |
Moderate |
Scalp, trunk, and pediatric use |
| Solution |
Easy application to hair-bearing skin |
Moderate |
Scalp and intertriginous areas |
| Gel |
Lower residue and faster drying |
Moderate to high |
Facial and oily-skin applications |
| Foam |
Fast application and cosmetic acceptance |
High |
Scalp and large-area use |
| Spray |
Contact-minimizing delivery |
High |
Difficult-to-reach or painful areas |
| Anhydrous balm |
Preservative reduction and high occlusion |
Moderate |
Barrier-compromised skin |
A lotion, gel, foam, or spray would offer the clearest differentiation from conventional generic cream. A new vehicle can also create a stronger product franchise if it improves application to the scalp, hairy areas, or large body surfaces.
What FDA pathway applies to a new clocortolone pivalate product?
A conventional generic cream may qualify for an ANDA if it demonstrates pharmaceutical equivalence and bioequivalence to the reference product. For topical products, FDA may require comparative physicochemical characterization, in vitro release testing, and other evidence specified in product-specific guidance or applicable regulatory standards.[2]
A materially different vehicle or dosage form may not fit a straightforward ANDA strategy. A 505(b)(2) application could be appropriate where the sponsor relies partly on FDA findings for an existing clocortolone pivalate product but introduces a new formulation, delivery system, indication, or clinical-use profile.[3]
Key development questions include:
- Whether the new dosage form has the same route and active concentration.
- Whether the formulation is qualitatively and quantitatively comparable to the reference product.
- Whether the vehicle changes local exposure or drug release.
- Whether clinical endpoint studies are needed.
- Whether the proposed label contains claims beyond the reference product.
- Whether the product can demonstrate therapeutic equivalence for pharmacy substitution.
A new topical dosage form may avoid direct generic price competition, but it will face higher development costs and a more demanding evidence package.
When does clocortolone pivalate lose exclusivity?
Clocortolone pivalate is an old active pharmaceutical ingredient, and the principal commercial opportunity is post-exclusivity competition. The original product and any early formulation patents are not the primary barrier to entry for current developers.
The Orange Book is the relevant FDA source for approved products, patent listings, exclusivity periods, and therapeutic-equivalence information.[4] A sponsor assessing a specific reference product should review the current Orange Book entry, FDA approval history, and product-specific labeling before relying on patent or substitution conclusions.
The practical exclusivity position is:
| Exclusivity category |
Commercial assessment |
| Original composition-of-matter exclusivity |
Historical and expired |
| Original formulation protection |
Historical; assess any later patents separately |
| Current new chemical entity exclusivity |
Not applicable to this established ingredient |
| Pediatric exclusivity |
Product-specific and not expected to define the active ingredient market |
| Orphan exclusivity |
Not a central commercial feature |
| Active Orange Book patent barrier |
Must be verified against the current listed product |
| Formulation or device protection |
Potentially available for a new product |
The protectable asset in a new program would more likely be a formulation, delivery device, manufacturing process, package, dosing regimen, or combination claim than the active molecule itself.
Are Paragraph IV challenges relevant to clocortolone pivalate?
Paragraph IV litigation is most relevant when an ANDA applicant challenges an Orange Book-listed patent for a branded reference product. For an old topical corticosteroid, the major market risk is usually routine generic entry rather than a prolonged patent dispute.
A Paragraph IV strategy could become relevant if a sponsor obtains FDA approval for a new branded cream, foam, gel, or device and lists qualifying patents in the Orange Book. Potential patent categories include:
- Specific excipient ratios.
- Particle-size or drug-state limitations.
- Emulsion architecture.
- Preservative-free packaging.
- Metered-dose delivery.
- Manufacturing conditions that produce a defined microstructure.
- Methods of treating a defined dermatosis or body site.
A patent that merely claims clocortolone pivalate in a conventional cream would face substantial validity and obviousness pressure. Stronger claims would tie the formulation to measurable performance, such as a defined release profile, improved stability, reduced irritation, or a specific device-product combination.
How strong is the patent estate for clocortolone pivalate?
The active-ingredient patent estate is commercially weak because clocortolone pivalate is an established corticosteroid. A new sponsor would need to build protection around product-specific innovations.
| Patent layer |
Relative strength |
Main vulnerability |
| Active ingredient |
Low |
Prior art and expired historical rights |
| Conventional 0.1% cream |
Low to moderate |
Obviousness and routine formulation arguments |
| Narrow excipient ranges |
Moderate |
Design-around and lack of unexpected results |
| Preservative-free package |
Moderate |
Enablement and obviousness issues |
| Foam, gel, or spray delivery |
Moderate to high |
Prior art and clinical equivalence requirements |
| Device-formulation combination |
Moderate to high |
Claim scope and device substitution |
| Manufacturing process |
Moderate |
Independent development and process replication |
| Method of use |
Moderate |
Label overlap and written-description limits |
Patent strength depends on comparative data. Unexpected advantages, such as lower irritation with equivalent efficacy, improved stability under accelerated conditions, or superior patient adherence, can materially improve enforceability and licensing value.
What commercial opportunities exist for excipient suppliers and manufacturers?
Commercial opportunities fall into four segments.
Generic supply
A manufacturer can compete on cost, reliable API supply, manufacturing yield, and pharmacy availability. This is the lowest-risk strategy but usually produces the lowest margin. The product must meet topical equivalence and quality expectations while controlling emulsion variability.
Branded reformulation
A reformulated clocortolone pivalate product can target patients who reject greasy creams, have preservative sensitivity, need scalp application, or require treatment over larger areas. A branded reformulation needs differentiated clinical or usability evidence to support a premium.
Specialty dermatology licensing
A company with a validated vehicle platform could license a clocortolone pivalate product to a dermatology-focused commercial partner. The most attractive assets would have:
- A clear dosage-form difference.
- Patent claims directed to the formulation or device.
- Evidence of improved cosmetic acceptability.
- A defined target population.
- Manufacturing scalability.
- A credible reimbursement strategy.
Contract development and manufacturing
Topical products create opportunities for manufacturers with expertise in emulsion scale-up, homogenization, microbial control, filling, airless packaging, and tube or pump compatibility. Scale-up risk is material because laboratory emulsion properties may not transfer directly to commercial equipment.
What manufacturing and IP barriers affect market entry?
The main technical barriers are not API synthesis. They are formulation reproducibility and product performance.
Critical manufacturing controls include:
- API particle-size distribution and dispersion.
- Order and temperature of phase addition.
- Homogenization energy and mixing time.
- Cooling profile.
- Viscosity and rheology.
- Droplet-size distribution.
- Content uniformity.
- Microbial limits and preservative effectiveness.
- Tube, pump, or container compatibility.
- Long-term and accelerated stability.
Topical manufacturing changes can alter drug release without changing labeled strength. A manufacturer therefore needs tight process controls and comparative performance data. Packaging is also part of the formulation strategy. Airless pumps, unit-dose packages, and metered dispensers can support premium positioning but raise component cost and qualification requirements.
How does clocortolone pivalate compare with competing topical corticosteroids?
Clocortolone pivalate competes with hydrocortisone, desonide, triamcinolone acetonide, betamethasone products, fluocinolone acetonide, and other topical corticosteroids. Prescribing decisions depend on potency, body site, lesion severity, age, treatment duration, vehicle, price, and patient preference.
| Product category |
Typical competitive position |
| Hydrocortisone |
Lower potency, broad availability, low price |
| Desonide |
Low-potency branded and generic competition |
| Clocortolone pivalate |
Medium-potency positioning with room for vehicle differentiation |
| Triamcinolone acetonide |
Broad generic competition across multiple vehicles |
| Betamethasone products |
Higher-potency options with stronger site and duration restrictions |
| Fluocinolone acetonide |
Multiple vehicles, including oil and solution products |
Clocortolone pivalate is most commercially defensible where its vehicle improves adherence or tolerability relative to inexpensive medium-potency alternatives. A price-only strategy faces direct competition from triamcinolone and other generic corticosteroids.
What generic launch risks exist?
A generic launch can occur through direct approval of a cream, an authorized generic arrangement, or development of a distinct dosage form. Key risks include:
- Limited market size relative to development costs.
- Low reimbursement and rapid price erosion.
- Multiple generic entrants.
- Difficulty demonstrating topical equivalence.
- Low switching barriers among prescribers and pharmacies.
- Weak differentiation from triamcinolone products.
- Formulation instability during scale-up.
- Container-closure compatibility problems.
- Limited ability to support premium pricing.
A differentiated product should avoid competing solely on the active ingredient. The strongest launch case combines a clear patient-use advantage with a defensible formulation or device patent.
What geographic markets offer opportunities?
The United States offers the clearest regulatory framework for ANDA and 505(b)(2) development, but topical corticosteroid markets are competitive in North America, Europe, Japan, and other regulated jurisdictions.
Geographic strategy should account for:
- Different reference products and approved strengths.
- Country-specific prescription status.
- Local excipient restrictions.
- Separate patent registers and linkage systems.
- Different therapeutic-equivalence standards.
- Reimbursement and dermatology prescribing patterns.
- Packaging and labeling requirements.
- Local manufacturing or import controls.
A formulation designed for global use should avoid excipients that create regional regulatory or allergen-labeling problems. Preservative-free or low-allergen systems may provide the broadest international positioning, but they also impose greater stability and packaging requirements.
Key Takeaways
- Clocortolone pivalate is an established medium-potency topical corticosteroid, marketed primarily as a 0.1% cream.
- The active ingredient is not the principal source of new commercial exclusivity.
- Excipient opportunities center on low irritation, lower residue, barrier support, preservative reduction, and improved application.
- Lotion, gel, foam, spray, and metered-dose products offer greater differentiation than another conventional cream.
- A standard comparable cream may fit an ANDA pathway, while a materially different dosage form may require a 505(b)(2) strategy.
- Stronger patents would claim measurable formulation, delivery, manufacturing, or device advantages.
- Generic competition is likely to pressure pricing, making adherence and cosmetic performance central to premium positioning.
- The most attractive licensing assets combine a differentiated vehicle, patentable formulation features, clinical usability data, and scalable manufacturing.
FAQs About Clocortolone Pivalate Formulation and Commercial Strategy
Can clocortolone pivalate be formulated as a preservative-free cream?
Yes. A preservative-free product would require validated microbial control through formulation design, manufacturing controls, packaging, or a combination of these measures. Anhydrous systems and unit-dose or airless packaging are potential approaches.
Is clocortolone pivalate suitable for a foam product?
Yes, but a foam would require substantial development work. The sponsor would need to establish API uniformity, foam stability, dose delivery, container compatibility, flammability controls where relevant, and comparable clinical performance.
Would a new clocortolone pivalate gel automatically qualify as a generic?
No. A gel with a materially different vehicle may not meet the requirements for a conventional ANDA. FDA could require additional comparative performance or clinical evidence depending on the formulation and proposed labeling.
What excipient creates the strongest commercial differentiation?
No single excipient is likely to create durable differentiation. The strongest opportunity is a complete vehicle system that produces lower irritation, better cosmetic acceptance, stable drug delivery, and a defensible patent position.
Can a clocortolone pivalate formulation be sold over the counter?
Not through the standard topical corticosteroid OTC monograph. A switch would require FDA review and supporting evidence for the proposed concentration, labeling, safety profile, and self-use conditions.
References
- U.S. Food and Drug Administration. (n.d.). Clocortolone pivalate cream, USP 0.1% prescribing information. DailyMed.
- U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development. FDA.
- U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). FDA.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
